

IN THE SPECIFICATION:

Please amend the specification as follows. A copy of the marked-up version of the amendment to the specification is provided as Exhibit A

On pages i and 1, replace the title of the invention with the following title:

C1
METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE
CONDITIONS BY PERIPHERALLY ADMINISTERED ERYTHROPOIETIN

On page 1, replace the first paragraph with the following paragraph:

C2
This application claims priority under 35 U.S.C. §119(e) to U.S. provisional patent Application No. 60/129,131 filed April 13, 1999 and under 35 U.S.C. §120 to U.S. Application No. 09/547,220 filed April 11, 2000, the entire contents of both of which are incorporated herein by reference in its their entirety.

On page 7, replace the second paragraph with the following paragraph:

C3
FIG. 3A-C. A. The results of an experiment which demonstrates that peripherally-administered EPO pretreatment reduces seizure severity and protects mice from convulsions and death by the neurotoxin kainate. The numbers in parentheses under each column indicate the number of animals receiving each kainate dose. B shows that the protective effects of peripherally-administered EPO increase with daily administration of EPO. C illustrates that the onset of action of EPO is delayed, characteristic of the induction of a gene expression program.

IN THE CLAIMS:

Please amend the claims as follows. A copy of the marked-up version of the claim amendment is provided as Exhibit B, and a copy of the claims that will be pending upon entry of the instant amendment is provided as Exhibit C.

Cancel Claims 7 and 10.

Amend Claims 1, 2, and 9 to read as follows:

C4 Sub D1
1. (amended) A method for the prevention or treatment of a neurodegenerative condition comprising administering peripherally to a mammal an effective non-toxic amount of EPO.